Trial Profile

A phase 3 study of LX9211 in painful diabetic neuropathy

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 10 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

06 Mar 2025 According to Lexicon Pharmaceuticals Media Release, company is moving toward an end of Phase 2 meeting with FDA and targeting initiation of U.S. and ex-U.S. Phase 3 trials in DPNP in 2025, while selecting a future medical meeting for release of additional clinical data later this year.
03 Mar 2025 According to Lexicon Pharmaceuticals Media Release, company has identified 10 mg once daily as an appropriate dose to advance into Phase 3 clinical development for DPNP.
27 Nov 2024 According to Lexicon Pharmaceuticals Media Releae, the company anticipated to share top-line findings from the study early next year.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com